Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: IMMU
- CUSIP: 45290710
- Previous Close: $5.34
- 50 Day Moving Average: $4.13
- 200 Day Moving Average: $3.20
- 52-Week Range: $106,079,000.00 - $1.91
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 267.00
- P/E Growth: 0.00
- Market Cap: $566.46M
- Outstanding Shares: 106,079,000
- Beta: 1.68
- Net Margins: -2,385.59%
- Return on Assets: -116.00%
Companies Related to Immunomedics:
- Debt-to-Equity Ratio: -1.30%
- Current Ratio: 1.69%
- Quick Ratio: 1.67%
What is Immunomedics' stock symbol?
Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."
Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2017?
2 brokers have issued 1 year price targets for Immunomedics' stock. Their forecasts range from $5.50 to $5.50. On average, they anticipate Immunomedics' stock price to reach $5.50 in the next year.
When will Immunomedics announce their earnings?
Immunomedics is scheduled to release their next quarterly earnings announcement on Thursday, February, 9th 2017.
Who owns Immunomedics stock?
Immunomedics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include First Light Asset Management LLC (2.15%), State Street Corp (1.52%), Arrowpoint Asset Management LLC (1.44%), FMR LLC (1.07%), State Board of Administration of Florida Retirement System (0.09%) and Metropolitan Life Insurance Co. NY (0.06%). Company insiders that own Immunomedics stock include Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark and Mary E Paetzold.
Who bought Immunomedics stock? Who is buying Immunomedics stock?
Immunomedics' stock was purchased by a variety of institutional investors in the last quarter, including Arrowpoint Asset Management LLC, First Light Asset Management LLC, State Street Corp, Two Sigma Investments LP and Metropolitan Life Insurance Co. NY.
How do I buy Immunomedics stock?
Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Immunomedics stock cost?
One share of Immunomedics stock can currently be purchased for approximately $5.34.